Seres Therapeutics Inc. (NASDAQ:MCRB) shot up 3.4% during trading on Monday . The stock traded as high as $11.57 and last traded at $11.41, with a volume of 427,784 shares traded. The stock had previously closed at $11.04.

Several research firms recently commented on MCRB. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, May 2nd. Canaccord Genuity reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, June 13th. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. Finally, Leerink Swann restated a “buy” rating and issued a $12.00 price target on shares of Seres Therapeutics in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $31.57.

The company’s market capitalization is $458.72 million. The firm’s 50 day moving average is $22.28 and its 200-day moving average is $26.31.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The company had revenue of $3 million for the quarter, compared to the consensus estimate of $4.20 million. During the same quarter last year, the business posted ($1.45) EPS. The company’s revenue was up NaN% compared to the same quarter last year. Equities research analysts expect that Seres Therapeutics Inc. will post ($2.32) earnings per share for the current fiscal year.

In other Seres Therapeutics news, insider Michele Trucksis sold 4,156 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $35.18, for a total transaction of $146,208.08. Following the transaction, the insider now directly owns 4,156 shares in the company, valued at $146,208.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total transaction of $27,600,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Jennison Associates LLC raised its position in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 398,959 shares of the company’s stock after buying an additional 7,259 shares during the period. Jennison Associates LLC owned 1.02% of Seres Therapeutics worth $13,999,000 as of its most recent SEC filing.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.